Clinical Trial Update: Effects of Erythropoietin on Cognition and Neural Activity in Mood Disorders [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the effects of erythropoietin on cognition and neural activity in mood disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Cognitive Impairment
• Unipolar Depression

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: Lars Vedel Kessing | Conditions: Bipolar Disorder, Cognitive Impairment | Phase 2 | Status: COMPLETED